NT, my sentiments exactly. Some have compared this AS increase with the last one from 250M to 1B shares and are worried about further dilution. But we didn't have a defined funding plan back then. Now we do, and that LPC agreement will allow the company to tap another $18M without exceeding the current AS, as you stated, and it will fund the company and existing initiatives into 2016, well past the point of revenue generation with LymPro.

So it seems reasonable to conclude that since funding conditions are substantially different than the last AS increase, the additional shares will be used for strategic acquisitions and potential spinoff of the diagnostics division. I feel the concerns over additional dilution for funding going forward are not realistic, as we are in a much better position now than anytime in the past. CFO Robert Farrell confirmed this and stated in the latest business update call that the company is in the best financial shape it's been in the last year, and that the additional R&D costs anticipated can all be funded with the existing LPC funding.